Eisai, GE reach R&D deal for Alzheimer's

04/28/2013 | DOTMed.com · AuntMinnie.com (free registration)

GE Healthcare has announced a collaboration with Eisai focused on research and development of treatments for Alzheimer's disease. GE said its candidate PET agent flutemetamol will be used by Eisai in choosing patients for an early-stage study of Eisai's beta-site amyloid precursor protein-cleaving enzyme inhibitor E2609 as a possible treatment for the disease.

View Full Article in:

DOTMed.com · AuntMinnie.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance Director
Abbott Laboratories
Santa Clara, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA